Department of Pathology, Division of Experimental Cardiology, Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, Netherlands; Department of Nephrology and Hypertension, DIGD, University Medical Center Utrecht, Utrecht, Netherlands.
Neuro Oncol. 2017 Oct 19;19(11):1435-1446. doi: 10.1093/neuonc/nox081.
"Tumor-associated macrophages" (TAMs) form a significant cell population in malignant tumors and contribute to tumor growth, metastasis, and neovascularization. Gliomas are characterized by extensive neo-angiogenesis, and knowledge of the role of TAMs in neovascularization is important for future anti-angiogenic therapies. The phenotypes and functions of TAMs are heterogeneous and more complex than a classification into M1 and M2 inflammation response types would suggest. In this review, we provide an update on the current knowledge of the ontogeny of TAMs, focusing on diffuse gliomas. The role of TAMs in the regulation of the different processes in tumor angiogenesis is highlighted and the most recently discovered mechanisms by which TAMs mediate resistance against current antivascular therapies are mentioned. Novel compounds tested in clinical trials are discussed and brought in relation to different TAM-related angiogenesis pathways. In addition, potential therapeutic targets used to intervene in TAM-regulated tumor angiogenesis are summarized.
“肿瘤相关巨噬细胞”(TAMs)是恶性肿瘤中重要的细胞群体,促进肿瘤生长、转移和新生血管形成。神经胶质瘤以广泛的新生血管形成为特征,了解 TAMs 在新生血管形成中的作用对于未来的抗血管生成治疗至关重要。TAMs 的表型和功能具有异质性,比 M1 和 M2 炎症反应类型的分类更为复杂。在这篇综述中,我们提供了 TAMs 发生发展的最新知识更新,重点关注弥漫性神经胶质瘤。强调了 TAMs 在肿瘤血管生成不同过程中的调控作用,并提到了 TAMs 介导对抗当前抗血管生成治疗的耐药性的最新发现机制。讨论了临床试验中测试的新型化合物,并将其与不同的 TAM 相关血管生成途径联系起来。此外,总结了用于干预 TAM 调节的肿瘤血管生成的潜在治疗靶点。